Publications by authors named "Fernando Terron"

Claim this Profile
E
Evaluation of the novel therapeutic anti-CCR7 antibody CAP-100 as an add-on therapy in chronic lymphocytic leukemia patients receiving venetoclax.
Tamara Mateu-Albero, Ana Marcos-Jimenez, Pablo Delgado-Wicke, Fernando Terrón, Javier Loscertales

Hematol Oncol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib Does Not Impact CCR7-Mediated Homeostatic Migration in T-Cells from Chronic Lymphocytic Leukemia Patients.
Tamara Mateu-Albero, Ana Marcos-Jimenez, Stefanie Wissmann, Javier Loscertales, Fernando Terrón

Cancers (Basel)· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of ibrutinib on CCR7 expression and functionality in chronic lymphocytic leukemia and its implication for the activity of CAP-100, a novel therapeutic anti-CCR7 antibody.
Tamara Mateu-Albero, Raquel Juárez-Sánchez, Javier Loscertales, Wim Mol, Fernando Terrón

Cancer Immunol Immunother· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting cancer homing into the lymph node with a novel anti-CCR7 therapeutic antibody: the paradigm of CLL.
Carlos Cuesta-Mateos, Raquel Juárez-Sánchez, Tamara Mateu-Albero, Javier Loscertales, Wim Mol

MAbs· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Of Lymph Nodes and CLL Cells: Deciphering the Role of CCR7 in the Pathogenesis of CLL and Understanding Its Potential as Therapeutic Target.
Carlos Cuesta-Mateos, Jennifer R Brown, Fernando Terrón, Cecilia Muñoz-Calleja

Front Immunol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CCR7 in Blood Cancers - Review of Its Pathophysiological Roles and the Potential as a Therapeutic Target.
Carlos Cuesta-Mateos, Fernando Terrón, Marco Herling

Front Oncol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CCR7 as a novel therapeutic target in t-cell PROLYMPHOCYTIC leukemia.
Carlos Cuesta-Mateos, Patricia Fuentes, Alexandra Schrader, Raquel Juárez-Sánchez, Javier Loscertales

Biomark Res· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical activity of anti-CCR7 immunotherapy in patients with high-risk chronic lymphocytic leukemia.
Carlos Cuesta-Mateos, Javier Loscertales, Anna Kreutzman, Beatriz Colom-Fernández, Itxaso Portero-Sáinz

Cancer Immunol Immunother· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-CCR7 therapy exerts a potent anti-tumor activity in a xenograft model of human mantle cell lymphoma.
Beatriz Somovilla-Crespo, Manuel Alfonso-Pérez, Carlos Cuesta-Mateos, Cristina Carballo-de Dios, Amada E Beltrán

J Hematol Oncol· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis